Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

ts or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed.

FINANCIAL DETAILS

-- Total revenue, resulting entirely from net Keflex product sales, was

$3.1 million in the third quarter of 2007, up from revenue of

$2.7 million in the prior quarter, and $2.4 million for the third

quarter of 2006. Revenue for the quarter included $1.8 million that

had been deferred in the previous quarter, as well as one month's

actual sales in the quarter as the company resumed shipments of product

in September upon completion of relabeling. Revenue during the first

nine months of 2007 was $7.6 million, up from revenue of $3.6 million

during the first nine months of 2006. Increased product sales were

mainly attributable to the Company's Keflex 750 mg strength capsules

which were launched during the third quarter of 2006.

-- Operating expenses. Third quarter research and development expenses,

primarily consisting of salaries, stock-based compensation, and related

expenses for personnel and the costs of the Company's clinical trials

and research initiatives, were $5.5 million, compared to $5.4 million

in the previous quarter and $5.7 million in the third quarter of 2006.

Additional costs of $0.8 million were incurred in the third quarter as

the Company consolidated operations into a single site, but these were

offset by lower personnel costs and reduced spending on developing the

Company's amoxicillin manufacturing facility.

Selling, general and administrative (SG&A) expenses totaled

$6.5 million in the third quarter of 2007, up from $6.3 million in the

second quarter of 2007, and $6.1 million in the third quarter of 20
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... NY (PRWEB) December 20, 2014 ... allege a metal-on-metal version of the artificial hip ... in state and federal courts, Bernstein Liebhard LLP ... Jersey’ Bergen County Superior Court on December 2nd, ... to begin deposition of plaintiffs on November 19, ...
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
(Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
(Date:12/19/2014)... Today, Balfleet.com , a leading ... its formal dress promotion. All the old and new ... off. , Balfleet.com is well-known for its high quality ... dresses, cocktail dresses and more. Its formal dresses are ... and they can create an elegant look when paired ...
(Date:12/19/2014)... Anaheim, CA (PRWEB) December 19, 2014 ... not-for-profit corporation dedicated to developing educational events, tools ... and Rouxbe Cooking School , the world’s ... develop the prescription every human being needs: Culinary ... and plant-based cooking course, Culinary Rx, scheduled for ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4
... , DURHAM, N.C., Oct. 19 Oxygen Biotherapeutics, Inc. (OTC ... reverse stock split. The vote was part of a general ... management,s nominees to the company board of directors. , At ... for the formal launch of the company,s Dermacyte(TM) Oxygen Concentrate ...
... blocked protects tissue, animal study finds, , MONDAY, Oct. ... shown in animal studies that providing supplemental oxygen during ... it,s not a simple matter. Success in preventing brain ... percent oxygen is given. , "The use of ...
... or suppliers in states that permit use of the drug ... has decided it will no longer prosecute medical marijuana users ... allow use of the drug for medicinal purposes. , The ... Department memo to federal prosecutors on Monday, are designed to ...
... Va.Seven medical imaging groups wrote a joint letter to ... formally request coverage of two fluorodeoxyglucose (FDG) positron emission ... treatment evaluation. Currently, CMS covers only one FDG-PET study ... contrary to good clinical practice under certain circumstances. ...
... dextrose right after surgery quells upset stomach, researchers say ... suggests that patients need not fear post-operative nausea and ... of glucose. , "As one of the most ... the main causes of decreased patient satisfaction following surgery," ...
... At the 2009 Fryeburg Fair, concluded on October ... Best Educational Display. Fryeburg Fair President Roy Andrews, along ... at the fairgrounds. , The award recognizes Poland Spring ... Natural Resources Pavilion. According to Poland Spring Natural Resource ...
Cached Medicine News:Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 3Health News:Timing of Oxygen After a Stroke May Matter 2Health News:U.S. Relaxes Opposition to Medical Marijuana 2Health News:U.S. Relaxes Opposition to Medical Marijuana 3Health News:1 scan per patient is not always enough 2Health News:Easy Way to Prevent Post-Op Nausea? 2Health News:Fryeburg Fair Awards Poland Spring Team 'Best Educational Display' 2
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
(Date:12/19/2014)... SAN DIEGO , Dec. 18, 2014  RESMED INC. ... report its second quarter of fiscal year 2015 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
(Date:12/19/2014)... development with the growth pace keeping at 20%-30% in last ... size of China separating membrane products ... 16.3%. It is projected that China ... 20% in the upcoming years and that the figure by ... integrated membrane industrial system has taken shape in ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... , , , , , , , , ... PARIS and LAUSANNE, Switzerland , February 4 ... and Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies ... unmet medical needs, announce the launch by,Ipsen in France ...
... , , ST. LOUIS , Feb. ... that its Board of Directors declared a quarterly dividend of ... to all shareholders of record on February 15, ... and equipment used by dentists, dental hygienists, dental assistants, and ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Young Innovations, Inc. Board of Directors Declares Quarterly Dividend 2
With this more compact transducer face, this is the transducer of choice for obstetric imaging in areas with a small acoustic window....
... convex array is designed with the smaller ... with this multi-frequency transducer is ideal for ... of quick and accurate diagnoses. A choice ... need, and allows you to obtain high ...
... new XL3000 by PerkinElmer,is a ... latest in,Cermax Xenon technology.,Cermax Xenon ... technology,for integration into endoscopy,equipment and ... accurate color illumination.,It provides many ...
... Test System* is a multiplexed, fluorescent, ... multiple assays from a single sample ... a simple and streamlined alternative to ... clinical sensitivity and comparable clinical specificity ...
Medicine Products: